Q-omics provides the consensus-scored KLB profile across patient tissues and cancer cell-line models. KLB expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, KLB is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, KLB RNA expression shows 15,925 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, COAD, and UVM as cancer lineages where KLB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLB survival associations across molecular data types. KLB RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLB RNA expression–survival associations across cancer types. High KLB expression shows unfavorable associations in OV and DLBC, but favorable associations in LUAD, LGG, PAAD and HNSC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for KLB RNA expression.
This table summarizes KLB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for KLB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLB shows lower tumor expression in COAD, HNSC, THCA, LUAD, BRCA and LUSC. The COAD box plot shows higher KLB RNA expression in normal versus tumor tissue (log2 FC = −0.982, t-test p < 0.001).
This table shows molecular features associated with KLB in patient tissues and cancer cell lines. In patient samples, KLB shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, KLB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Lymphoma.
